Navigation Links
Ardea Biosciences to Present at Two Upcoming Investor Conferences
Date:5/4/2011

SAN DIEGO, May 4, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that Barry D. Quart, PharmD, president and chief executive officer, will present at the following upcoming investor conferences:

  • Tenth Annual JMP Securities Research Conference in San Francisco, CA. Presentation: 9:30 a.m. PDT on Monday, May 9, 2011.
  • Bank of America Merrill Lynch 2011 Healthcare Conference in Las Vegas, NV. Presentation: 1:00 p.m. PDT on Tuesday, May 10, 2011.

About Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases. Lesinurad (RDEA594), our lead product candidate for the treatment of hyperuricemia and gout, is a once-daily, oral inhibitor of the URAT1 transporter.  We have completed Phase 2b clinical studies of lesinurad and continue to advance the drug in longer term extensions in preparation for Phase 3 development.  Our next-generation URAT1 inhibitor program is currently in preclinical development. BAY 86-9766 (RDEA119), is a potent and specific inhibitor of mitogen-activated ERK kinase (MEK) for the treatment of cancer being developed under a global license agreement with Bayer HealthCare AG. BAY 86-9766 is currently in a Phase 2 study in patients with hepatocellular carcinoma in combination with sorafenib (Nexavar®; Bayer, Onyx Pharmaceuticals) and a Phase 1/Phase2 study in patients with advanced pancreatic cancer in combination with gemcitabine.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Such statements include, but are not limited to, statements regarding our plans and goals, the expected properties and benefits of lesinurad, BAY 86-9766 (RDEA119) and our other compounds and the timing and results of our preclinical, clinical and other studies.  Risks that contribute to the uncertain nature of the forward-looking statements include risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, costs associated with our drug discovery and development programs, and risks related to the outcome of our business development activities, including collaboration or license agreements.  These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under the headings "Risk Factors."  All forward-looking statements contained in this press release speak only as of the date on which they were made.  We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

(Logo:  http://photos.prnewswire.com/prnh/20091104/ARDEALOGO)


'/>"/>
SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ardea Biosciences Earns $15 Million Payment from Bayer HealthCare AG for Achievement of Important Clinical Milestone in Ongoing Collaboration
2. Ardea Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
3. Ardea Biosciences to Present at Four Upcoming Investor Conferences
4. Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance
5. Ardea Biosciences to Present at Two Upcoming Investor Conferences
6. Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results
7. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
8. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
9. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
10. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
11. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Executive Summary ... primary research (inputs from industry experts, companies, stakeholders) ... the analysis of global heart valve devices market ... Replacement Procedure By Technique (Mechanical, Bioprosthetic, Transcatheter Aortic ... Balloon Valvuloplasty, Transcatheter Mitral Valve Repair (TMVR)), By ...
(Date:3/23/2017)... , March 23, 2017 ... Pharmaceutical and Healthcare disease pipeline guide Primary Hyperoxaluria ... of the Primary Hyperoxaluria (Genito Urinary System And ... a rare condition characterized by recurrent kidney and ... a substance called oxalate. Symptoms include blood in ...
(Date:3/23/2017)... BELLEVUE, Wash. , March 23, 2017 /PRNewswire/ ... enterprise contract management in the cloud, today ... Agreement and Budgeting solution designed to improve clinical ... Contract Management (ICM) platform , the solution speeds ... compliance with contract research organizations (CRO). ...
Breaking Medicine Technology:
(Date:3/23/2017)... Holland, PA and Grimsby, Ontario (PRWEB) , ... March 23, 2017 , ... The MBI ... the modular industry or whose acts have had a significant impact on the careers of ... Sales and Marketing with NRB Inc. was inducted into the MBI’s Hall of Fame. ...
(Date:3/23/2017)... ... March 23, 2017 , ... March is National Kidney Month – ... when it comes to maintaining good health. Every day, two kidneys filter about 120 ... every drop of your blood, eliminating waste, regulating fluid levels and blood pressure, supporting ...
(Date:3/23/2017)... CA (PRWEB) , ... March 23, 2017 , ... ... funding investment in Los Angeles based healthcare technology company California Healthcom Group (CHG). ... into the US, and healthcare arena. With headquarters in California, CHG is a ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... businesses of the greater Fort Collins area, has unveiled a collaboration with nonprofit ... involvement program. Donations to this worthy cause may now be made at ...
(Date:3/23/2017)... Hills, CA (PRWEB) , ... March 23, 2017 ... ... document management and workflow solutions, today named The Resource Group as their 2016 ... customer and partner conference in Newport Beach, CA. The award recognizes The ...
Breaking Medicine News(10 mins):